Das Hanusch-Krankenhaus befindet sich im 14. Wiener Gemeindebezirk in der Heinrich-Collin-Straße 30. Es ist ein Krankenhaus mit zehn Abteilungen und sieben Instituten, darunter das Ludwig-Boltzmann-Institut, ein Forschungsinstitut für Osteologie und Leukämie-Forschung.

During the past decade, Hanusch Krankenhaus conducted 49 clinical trials. In the 10-year time frame, 49 clinical trials started and 15 clinical trials were completed, i.e. on average, 30.6% percent of trials that started reached the finish line to date. In the past 5 years, 20 clinical trials started and 11 clinical trials were completed. i.e. 55% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hanusch Krankenhaus" #1 sponsor was "Arbeitsgemeinschaft medikamentoese Tumortherapie" with 8 trials, followed by "German CLL Study Group" with 8 trials sponsored, "University of Ulm" with 8 trials sponsored, "AOP Orphan Pharmaceuticals AG" with 4 trials sponsored and "Celgene" with 4 trials sponsored. Other sponsors include 52 different institutions and companies that sponsored additional 47 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hanusch Krankenhaus" #1 collaborator was "Hoffmann-La Roche" with 4 trials as a collaborator, "Amgen" with 2 trials as a collaborator, "Cancer Trials Ireland" with 2 trials as a collaborator, "Concept Medical Inc." with 2 trials as a collaborator and "CoreLab Black Forest" with 2 trials as a collaborator. Other collaborators include 55 different institutions and companies that were collaborators in the rest 59 trials.

According to Clinical.Site data, the most researched conditions in "Hanusch Krankenhaus" are "Chronic Lymphocytic Leukemia" (7 trials), "Acute Myeloid Leukemia" (6 trials), "Peripheral Artery Disease" (5 trials), "Acute Myeloid Leukemia (AML)" (4 trials) and "Breast Cancer" (4 trials). Many other conditions were trialed in "Hanusch Krankenhaus" in a lesser frequency.

Most popular intervention types in "Hanusch Krankenhaus" are "Drug" (60 trials), "Device" (15 trials), "Biological" (11 trials), "Other" (5 trials) and "Procedure" (4 trials). Other intervention types were less common.

The name of intervention was led by "Cytarabine" (6 trials), "Cyclophosphamide" (5 trials), "Placebo" (5 trials), "Rituximab" (5 trials) and "Fludarabine" (4 trials). Other intervention names were less common.

The vast majority of trials in "Hanusch Krankenhaus" are 83 trials for "All" genders, 5 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Hanusch Krankenhaus". undefined are not yet recruiting, 12 are recruiting, 16 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 50 completed trials in Hanusch Krankenhaus, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Hanusch Krankenhaus, 6 "Phase 1" clinical trials were conducted, 23 "Phase 2" clinical trials and 41 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 13 trials that are defined as “Not Applicable".